Catalent and Minerva Neurosciences Enter Commercial Supply Agreement for Schizophrenia Drug Roluperidone
September 24, 2019 09:00 ET
|
Minerva Neurosciences, Inc
WALTHAM, Mass. and SOMERSET, N.Y., Sept. 24, 2019 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of innovative...